Biphasic Isophane Insulin

Indications & Dose:

Diabetes mellitus.
INDICATIONS:

Diabetes Mellitus

POSOLOGY AND METHOD OF ADMINISTRATION :

Dual-acting insulin containing both fast-acting and long-acting insulin. An injection should be followed by a meal or a snack containing carbohydrates Within 30 minutes.
Dual-acting (premixed) insulin products are usually given once or twice daily when a rapid initial effect together with a more prolonged effect is desired.

DOSAGE: Dosage is individual and determined in accordance with the needs of the patient. The individual insulin requirement is usually between 0.3 and 1.0 IU/kg/day. The daily insulin requirement may be higher in patients with insulin resistance (e.g during puberty in the young or due to obesity) and lower in patients with residual, endogenous insulin production. ]

In patients with diabetes mellitus optimized glycaemic control delays the onset of late diabetic complications. Optimised metabolic control, including close blood glucose monitoring, is therefore recommended.

Dosage adjustment: Renal or hepatic impairment may reduce insulin requirement.

Administration : For subcutaneous use. Mixtard is usually administered subcutaneously in the thigh or abdominal wall. If convenient, the gluteal region or the deltoid region may also be used. Subcutaneous injection into the abdominal wall ensures a faster absorption that from other infection sites.

Infection into a lifted skin fold minimises the risk of unintended intramuscular injection. Injection sites should be rotated within an anatomic region in order to avoid lipodystrophy.

Intramuscular administrations are possible under guidance by a physician. Insulin suspensions are never to be administered intravenously. 

INDICATIONS: Diabetes mellitus

Dosage

Subcutaneously in the thigh or in the abdominal wall. If convenient, the gluteal or deltoid region may be used Given soon after a meal.

The individual insulin requirement is usually between 0.5 and 1.0 Units/kg/day and this may be fully . The daily insulin requirement may be higher in patients with insulin resistance (e.g due to obesity), and lower in patients with residual endogenous insulin production.

For further assistance see literature.

Contraindications:

Hypoglycaemia. Hypersensitivity to human insulin or to any of the excipients 

CONTRAINDICATIONS Hypersensitivity

Side Effects:

Uncommon – Urticaria, rash

Very rare – Anaphylactic reaction Symptoms of generalized hypersensitivity may include generalized hypersensitivity may include generalized skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation, reduction in blood pressure and fainting/loss of consciousness. Gneralised hypersensitivity reactions are potentially life threatening.

Nervous system disorders

Very rare – Peripheral neuropathy Fast improvement in blood glucose control may be associated with a condition termed “acute painful neuropathy”, which is usually reversible.

Eye disorders

Very rare – Refraction disorders refraction anomalies may occur upon initiation of insulin therapy. These symptoms are usually of transitory nature.

Uncommon – Diabetic retinopathy Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy.

Skin and subcutaneous tissue disorders.

Uncommon – Lipodystrophy Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.

General disorders and administration site conditions Uncommon – Injection site reactions injection site reactions (redness, swelling, itching, pain and haematoma at the injection site) may occur during treatment with insulin. Most reactions are transitory and disappear during continued treatment.

Uncommon – Oedema

Oedema may occur upon initiation of insulin treatment.

Cautions:

Precautions:

Interaction:

Diabetes mellitus

Dosage

Subcutaneously in the thigh or in the abdominal wall. If convenient, the gluteal or deltoid region may be used Given soon after a meal. The individual insulin requirement is usually between 0.5 and 1.0 Units/kg/day and this may be fully . The daily insulin requirement may be higher in patients with insulin resistance (e.g due to obesity), and lower in patients with residual endogenous insulin production. For further assistance see literature. CONTRAINDICATIONS Hypersensitivity. 

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: